{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:54:19Z","timestamp":1788216859499,"version":"build-2803163510"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Our study examined the global, national, and regional trends in the incidence, mortality, and disability-adjusted life years (DALYs) associated with older people\u2019s acute myeloid leukemia (AML) over a 30\u2009years period. AML, which predominantly affects individuals aged 60\u201389, is known for its severity and unfavorable prognosis. By providing insights into the growing burden of AML, our research highlights the urgent need for effective interventions and support at various levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, we analyzed older people with AML aged 60\u201389 using the Global Burden of Disease (GBD) database for 2019. Our goal was to assess trends and characteristics by examining the incidence rate, mortality rate, DALYs, and estimated annual percentage change (EAPC). We aimed to provide a comprehensive understanding of the disease\u2019s trajectory and development.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In 2019, the older age group of 60 to 89\u2009years reported 61,559 new cases of AML, with the corresponding number of deaths being 53,620, and the estimated DALYs standing at 990,656. Over the last 30\u2009years, the incidence rate of AML in this age bracket increased by 1.67 per 100,000 people, the mortality rate rose by 1.57 per 100,000 people, and the rate of DALYs, indicative of disease burden, climbed by 1.42 per 100,000 people. High Socio-demographic Index (SDI) regions, particularly high-income North America and Australia, had the highest incidence rates. Germany had the highest incidence rate among the 204 countries analyzed, while Monaco reported the highest mortality and DALY rates. Smoking, high body mass index, occupational exposure to benzene, and formaldehyde were identified as significant risk factors associated with mortality from older people with AML in 2019.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study showed that the incidence, mortality, and DALY rates of AML in the older population were strongly correlated with the SDI, and these rates have been steadily increasing. This had become an increasingly serious global health issue, particularly in areas with a high SDI. We highlighted the urgency to focus more on this disease and called for the prompt implementation of appropriate preventive and control measures.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2023.1329529","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T04:50:35Z","timestamp":1704948635000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Global, national, and regional burden of acute myeloid leukemia among 60\u201389\u2009years-old individuals: insights from a study covering the period 1990 to 2019"],"prefix":"10.3389","volume":"11","author":[{"given":"Pengyin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","article-title":"Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Shimony","year":"2023","journal-title":"Am J Hematol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/s0140-6736(18)31041-9","article-title":"Acute Myeloid Leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.semcancer.2009.12.001","article-title":"Leukemia Stem Cells","volume":"20","author":"Lane","year":"2010","journal-title":"Semin Cancer Biol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1007\/s11864-022-00991-z","article-title":"How genetics can drive initial therapy choices for older patients with acute myeloid leukemia","volume":"23","author":"Moore","year":"2022","journal-title":"Curr Treat Options in Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1182\/blood.2021011619","article-title":"Mica\/B antibody induces macrophage-mediated immunity against acute myeloid leukemia","volume":"139","author":"Alves da Silva","year":"2022","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"695865","DOI":"10.3389\/fimmu.2021.695865","article-title":"Prognosis and characterization of immune microenvironment in acute myeloid leukemia through identification of an autophagy-related signature","volume":"12","author":"Fu","year":"2021","journal-title":"Front Immunol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1182\/bloodadvances.2020001920","article-title":"American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults","volume":"4","author":"Sekeres","year":"2020","journal-title":"Blood Adv"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jgo.2017.08.004","article-title":"Emerging therapeutic modalities for acute myeloid leukemia (Aml) in older adults","volume":"8","author":"Huang","year":"2017","journal-title":"J Geriatr Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current Progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s11912-022-01299-9","article-title":"Older patients with acute myeloid leukemia deserve individualized treatment","volume":"24","author":"de Leeuw","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13045-020-00908-z","article-title":"The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017","volume":"13","author":"Yi","year":"2020","journal-title":"J Hematol Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/s0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e12981","DOI":"10.1111\/ina.12981","article-title":"Global magnitude and long-term trend of ischemic heart disease burden attributed to household air pollution from solid fuels in 204 countries and territories, 1990-2019","volume":"32","author":"Zhao","year":"2022","journal-title":"Indoor Air"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jinf.2022.04.026","article-title":"Global magnitude of encephalitis burden and its evolving pattern over the past 30 years","volume":"84","author":"Wang","year":"2022","journal-title":"J Infect"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/s0140-6736(20)30752-2","article-title":"Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1001\/jamapediatrics.2023.2029","article-title":"Global, regional, and National Epidemiology of diabetes in children from 1990 to 2019","volume":"177","author":"Zhang","year":"2023","journal-title":"JAMA Pediatr"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/s0140-6736(14)61682-2","article-title":"Regional, and National age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the global burden of disease study 2013","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/s0140-6736(18)32279-7","article-title":"Prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.leukres.2018.04.009","article-title":"Chinese and Europeans with acute myeloid leukemia have discordant mutation topographies","volume":"70","author":"Zhang","year":"2018","journal-title":"Leuk Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/ijc.34720","article-title":"Nonchromosomal birth defects and risk of childhood acute leukemia: an assessment in 15000 leukemia cases and 46000 controls from the childhood Cancer and leukemia international consortium","volume":"154","author":"Lupo","year":"2023","journal-title":"Int J Cancer"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1101\/cshperspect.a030320","article-title":"Dnmt3a in leukemia","volume":"7","author":"Brunetti","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ccell.2016.11.017","article-title":"Fto plays an oncogenic role in acute myeloid leukemia as a N(6)-Methyladenosine Rna demethylase","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1182\/bloodadvances.2019000168","article-title":"An update on the molecular pathogenesis and potential therapeutic targeting of Aml with T(8,21)(Q22;Q22.1);Runx1-Runx1t1","volume":"4","author":"Al-Harbi","year":"2020","journal-title":"Blood Adv"},{"key":"ref26","volume-title":"Leukemia. Statpearls. Treasure Island (FL) with ineligible companies. Disclosure: Varun Lyengar declares no relevant financial relationships with ineligible companies. Disclosure: Shiva Kumar Mukkamalla declares no relevant financial relationships with ineligible companies. Disclosure: Alex Shimanovsky declares no relevant financial relationships with ineligible companies","author":"Chennamadhavuni","year":"2023"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3390\/ijms24044140","article-title":"Natural inhibitors of P-glycoprotein in acute myeloid leukemia","volume":"24","author":"Labbozzetta","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"17998","DOI":"10.1038\/s41598-017-18278-x","article-title":"Influence of body mass index on Incidence and prognosis of acute myeloid leukemia and acute Promyelocytic leukemia: a Meta-analysis","volume":"7","author":"Li","year":"2017","journal-title":"Sci Rep"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00277-022-04812-z","article-title":"The prognostic impact of cigarette smoking on survival in acute myeloid leukemia with Tp53 mutations and\/or 17p deletions","volume":"101","author":"Bi","year":"2022","journal-title":"Ann Hematol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/bjh.16683","article-title":"Smoking and Aml-another piece in the puzzle","volume":"190","author":"Krug","year":"2020","journal-title":"Br J Haematol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.hoc.2019.11.003","article-title":"Secondary acute myeloid leukemia: a primary challenge of diagnosis and treatment","volume":"34","author":"Winer","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e6869","DOI":"10.7759\/cureus.6869","article-title":"Acute myeloid leukemia presenting as thrombotic thrombocytopenic Purpura","volume":"12","author":"Kucharik","year":"2020","journal-title":"Cureus"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"e2023013","DOI":"10.4084\/mjhid.2023.013","article-title":"Fever of unknown origin and multidrug resistant organism colonization in Aml patients","volume":"15","author":"Guarnera","year":"2023","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/14787210.2020.1820863","article-title":"Management of Fever and Neutropenia in the adult patient with acute myeloid leukemia","volume":"19","author":"Peseski","year":"2021","journal-title":"Expert Rev Anti-Infect Ther"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1329529\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T04:50:39Z","timestamp":1704948639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1329529\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":34,"alternative-id":["10.3389\/fpubh.2023.1329529"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2023.1329529","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,11]]},"article-number":"1329529"}}